- Rayyan
- Consultation
- June 18, 2026
- No Comments
Blog Details
Introduction: The Imperative for Transparency in AI-Driven Pharmacovigilance
As artificial intelligence becomes deeply embedded in pharmacovigilance workflows—from automated adverse event detection to signal prioritization—the demand for transparency has evolved from a nice-to-have feature to a regulatory and operational necessity. The black-box nature of traditional deep learning models, while powerful in identifying patterns across massive datasets, presents significant challenges when medical reviewers, regulators, and patients need to understand why a particular safety signal was flagged or how an AI system arrived at its conclusions.
The market reflects this transformation. The global Explainable AI (XAI) market was valued at approximately $7.94 billion in 2024 and is projected to reach $30.26 billion by 2032, growing at a compound annual growth rate (CAGR) of 18.2%. Within healthcare specifically, XAI adoption is accelerating at an even faster pace—Explainable AI in medical imaging alone is forecasted to grow at 30.0% CAGR over the next decade. Three converging forces drive this surge: escalating regulatory scrutiny, the need for clinical trust in AI-assisted decisions, and mounting evidence that transparency directly correlates with safer, more effective pharmacovigilance outcomes.
For pharmaceutical companies and Contract Research Organizations (CROs), approximately 80% of professionals in the pharmaceutical and life sciences sectors now utilize AI in some capacity. Yet, the audit trail and interpretability requirements from regulatory bodies have intensified dramatically. The European Medicines Agency’s 2024 Reflection Paper on AI in the Medicinal Product Lifecycle explicitly emphasizes transparency, accessibility, validation, and continuous monitoring of AI systems. Similarly, the FDA’s January 2025 draft guidance on “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making” introduced a risk-based credibility assessment framework that demands clear documentation of how AI models reach their conclusions.
The stakes are particularly high in adverse event detection. Unlike consumer applications, where AI errors might cause minor inconveniences, pharmacovigilance mistakes can delay critical safety interventions, compromise patient well-being, or lead to unnecessary market withdrawals of beneficial medications. Explainability is no longer optional—it’s foundational to the future of AI-powered drug safety.



